Systemic autoimmune rheumatic diseases-associated interstitial lung disease: a pulmonologist's perspective

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Connective tissue disease (CTD)-associated interstitial lung disease (ILD) occurs in autoimmune disorders like systemic sclerosis and lupus.
• The term systemic autoimmune rheumatic diseases (SARDs)-ILD is now used more broadly, including rheumatoid arthritis.
• SARD-ILD poses significant morbidity and mortality risks, with symptoms ranging from mild to life-threatening.

Purpose of the Study:

• To provide a comprehensive overview of SARD-ILD, covering its epidemiology, pathology, diagnosis, and management.
• To highlight the importance of early recognition and multidisciplinary approaches in optimizing patient outcomes.

Main Methods:

• Review of epidemiological data on ILD prevalence in SARDs.
• Analysis of pathological components, including immune-mediated inflammation and fibrosis.
• Evaluation of diagnostic criteria involving clinical, serological, radiological, and histological data.
• Assessment of current therapeutic strategies, including immunosuppressive and anti-fibrotic agents.

Main Results:

• Fibrosis is a key pathological feature in SARD-ILD, driven by immune-mediated inflammation and tissue remodeling.
• Common histological patterns include nonspecific interstitial pneumonia and usual interstitial pneumonia, influencing prognosis.
• Treatment involves immunosuppressive therapy, with anti-fibrotic agents used for progressive cases.
• Disease management is stratified by severity, with specific guidelines for different progression rates.

Conclusions:

• SARD-ILD is a complex condition with variable prevalence and prognosis across different SARDs.
• A multidisciplinary approach integrating clinical, imaging, and histological data is crucial for accurate diagnosis.
• Current management focuses on immunosuppression and anti-fibrotic therapies, tailored to disease severity and progression.
• Early detection and timely intervention are critical for improving outcomes in SARD-ILD patients, with lung transplantation considered for severe cases.